201. Peri-operative use of sorafenib in liver transplantation: a time-to-event meta-analysis.
- Author
-
Qi HL, Zhuang BJ, Li CS, and Liu QY
- Subjects
- Antineoplastic Agents adverse effects, Chemotherapy, Adjuvant, Chi-Square Distribution, Humans, Kaplan-Meier Estimate, Liver Neoplasms mortality, Liver Neoplasms pathology, Niacinamide administration & dosage, Niacinamide adverse effects, Odds Ratio, Phenylurea Compounds adverse effects, Protein Kinase Inhibitors adverse effects, Risk Factors, Sorafenib, Time Factors, Treatment Outcome, Antineoplastic Agents administration & dosage, Liver Neoplasms drug therapy, Liver Neoplasms surgery, Liver Transplantation adverse effects, Liver Transplantation mortality, Neoadjuvant Therapy adverse effects, Neoadjuvant Therapy mortality, Niacinamide analogs & derivatives, Phenylurea Compounds administration & dosage, Protein Kinase Inhibitors administration & dosage
- Abstract
Aim: To evaluate whether the application of sorafenib during the peri-operative period of liver transplantation improves prognosis in liver cancer patients., Methods: We searched PubMed, EMBASE and MEDLINE for eligible articles. A total of 4 studies were found that fulfilled the previously agreed-upon standards. We then performed a systematic review and meta-analysis on the enrolled trials that met the inclusion criteria., Results: Out of the 104 studies identified in the database, 82 were not clinical experiments, and 18 did not fit the inclusion standards. Among the remaining 4 articles, only 1 was related to the preoperative use of sorafenib, whereas the other 3 were related to its postoperative use. As the heterogeneity among the 4 studies was high, with an I(2) of 86%, a randomized effect model was applied to pool the data. The application of sorafenib before liver transplantation had a hazard ratio (HR) of 3.29 with a 95% confidence interval (CI) of 0.33-32.56. The use of sorafenib after liver transplantation had an HR of 1.44 (95%CI: 0.27-7.71). The overall pooled HR was 1.68 (95%CI: 0.41-6.91)., Conclusion: The results showed that the use of sorafenib during the peri-operative period of liver transplantation did not improve patient survival significantly. In fact, sorafenib could even lead to a worse prognosis, as its use may increase the hazard of poor survival.
- Published
- 2015
- Full Text
- View/download PDF